LY3295668
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY3295668, covering 2026-04-24 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer [Phase 1, Phase 2]